Hurdle
Hurdle is a London-based diagnostics-as-a-service company that uses a multi-omics AI platform, a Federated AI Discovery Engine, and saliva-based NGS testing to deliver 400+ biomarkers and lab services to enterprise healthcare, telehealth, CRO, and consumer health customers across the UK, EU, and North America.
- Company typePrivate
- Founded2017
- HeadquartersLondon, United Kingdom
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What Hurdle does
Hurdle (legal entity: Chronomics Limited) is a London-headquartered diagnostics-as-a-service (DaaS) company, founded in 2017 and rebranded from Chronomics in November 2023. With between 51 and 100 employees and a New York office, Hurdle operates a multi-omics AI biomarker discovery platform anchored in saliva-based next-generation sequencing (NGS) and proprietary epigenetic biomarkers, including the InflammAge inflammation-age marker and a biological-age test first commercialized in 2020. The platform processes samples via CE/UKCA-marked collection kits manufactured under ISO 13485, analyzed through a UKAS/CQC-accredited lab network, with a catalogue of more than 400 tests and a cumulative volume of over 3 million diagnostic tests processed. A data asset covering 2 million+ patient records and petabytes of multi-modal data feeds the proprietary Federated AI Discovery Engine and the recently launched AI Risk Scores product line. Hurdle holds 3 patents in epigenetics and maintains a stacked compliance posture including ISO 27001, SOC 2, HIPAA, GDPR, and ISO 13485.
The platform is delivered through an API with no-code/low-code integration options, complemented by a Digital Patient Experience Platform, Clinics OneDX, and a Partner Dashboard (with a new Partner Portal launched in March 2025). Hurdle serves enterprise B2B customers across private healthcare providers, telehealth operators, contract research organizations (CROs), consumer health brands, and employee benefits platforms. Named customers and partners include Bayer (flagship InflammAge partner), Lindus Health, Numan, Stride, Eurofins, GeneHub, Univi, Biovie, and the University of Birmingham. Hurdle has raised $2.8M in disclosed funding from Outsized Ventures (June 2023), which remains its only institutional round on record.
Hurdle firmographics
Firmographics- Name
- Hurdle
- Legal name
- Chronomics Limited
- Website
- https://hurdle.bio
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Hurdle is a London-based diagnostics-as-a-service company that uses a multi-omics AI platform, a Federated AI Discovery Engine, and saliva-based NGS testing to deliver 400+ biomarkers and lab services to enterprise healthcare, telehealth, CRO, and consumer health customers across the UK, EU, and North America.
- Ownership category
- akta.pro rank
Hurdle industry classification
Industry- Product category
- Diagnostics-as-a-Service Platform
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), Custom Computer Programming Services (541511), Computer Systems Design Services (541512), Testing Laboratories and Services (54138)
- SIC
- Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), Services-Prepackaged Software (7372), Services-Computer Programming, Data Processing, Etc. (7370)
- akta.pro primary industry
- Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF)
- akta.pro secondary industries
- Bioinformatics & Multi-omics Analysis Software (HLAGAJAD), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF)
Keywords
Where Hurdle is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices3 records
Markets served
Hurdle business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- Biomarker R&D Services: Scientific consultancy and biomarker development services accelerating the biomarker discovery and validation process (3-10X faster than conventional approaches). Includes co-creation of custom biomarker panels with scientific and clinical teams.
- Diagnostics-as-a-Service (DaaS): End-to-end diagnostic testing infrastructure delivered as a modular service. Covers sample collection kits, logistics & fulfilment, lab testing, digital patient experience, and partner dashboard — offered as an integrated suite or as plug-and-play components. Revenue is generated through the provision of the full platform or individual modules to enterprise partners.
- Sample Collection Kit Sales: Branded test collection kits (CE marked) sold to healthcare providers, telehealth companies, and enterprise partners. Various kit types including blood, urine, saliva, stool, and more.
- Digital Medicine Platform Licensing: White-labelled digital medicine solution enabling consumer health brands to integrate personalised diagnostics. Deployed as a platform licence with custom branding.
- Lab Testing Services: Diagnostic test processing through a network of CQC/UKAS-accredited labs. Covers hundreds of test types across the UK and EU, with results delivered via the partner dashboard or white-labelled interface.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Multi-year contract | Custom enterprise contracts — pricing based on scope of services, volume, and integration requirements |
| Unit Pricing | Pay-as-you-go | Modular plug-and-play — individual components (kits, lab testing, API, dashboard) priced per unit or per test |
| Subscription | Annual | Clinics OneDX — self-serve all-in-one diagnostics ordering system for healthcare providers |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels7 records
Hurdle product offering
Product offeringCore offering
Hurdle combines AI-driven multi-omics biomarker R&D with an end-to-end Diagnostics-as-a-Service (DaaS) platform for enterprise healthcare customers. Its integrated offering spans proprietary biomarker discovery (DiscoverDx AI engine), CE/UKCA-marked custom-branded sample collection kit manufacturing, a UKAS/CQC-accredited lab testing network, logistics and fulfilment, a white-labelled digital patient experience, and a partner dashboard accessible via a unified API or no-code interface.
Product overview
Hurdle offers a unified Diagnostics-as-a-Service (DaaS) platform that combines biomarker R&D (powered by DiscoverDx AI engine), sample collection kits (CE/UKCA marked), UKAS/CQC-accredited lab testing network, logistics and fulfilment, digital patient experience, and partner dashboard into a single integrated solution. The platform is designed for healthcare providers, telehealth companies, consumer health brands, clinical research organisations, and employee benefits consultants. Integration options include no-code (LabShop templates), low-code (customizable workflows), and full API access. The Test Catalogue provides 400+ clinically validated tests while the Federated AI Discovery Engine enables multi-institutional biomarker research without data centralization.
Differentiator
Problem solved
Functional benefit
Brands
- DiscoverDx: Multi-omics AI-powered biomarker discovery engine used in partnership with Bayer for developing novel diagnostics including the InflammAge biomarker.
Products and services
- Diagnostics-as-a-Service (DaaS) Platform End-to-end diagnostic testing infrastructure delivered as a modular managed service, covering biomarker R&D, custom-branded sample collection kits, UKAS/CQC-accredited lab testing, logistics and fulfilment, a white-labelled digital patient experience, and a partner dashboard — sold to healthcare providers, telehealth firms, CROs, pharma, and consumer health brands via custom enterprise contracts and the unified Hurdle API.
- Biomarker R&D Services AI-driven biomarker discovery and validation services leveraging DiscoverDx and multi-omics datasets to identify and develop novel biomarkers for complex risk factors and diseases, supporting regulatory submissions for enterprise partners.
- Sample Collection Kits Custom-branded CE/UKCA-marked sample collection kits with validated accuracy covering blood, saliva, urine, stool, and swab specimen types, sold to healthcare providers, telehealth companies, and enterprise partners as standalone products or as part of DaaS programmes.
- Lab Testing Services Diagnostic test processing delivered through a hand-picked network of CQC/UKAS-accredited labs across the UK and EU, covering hundreds of test types with results delivered via the partner dashboard or white-labelled interface, sold as a standalone service or as part of DaaS.
- Clinics OneDX Self-contained, no-code all-in-one diagnostics ordering system designed for healthcare providers and clinics that do not have developers on staff, providing pre-built templates for rapid deployment and direct access to the Hurdle test catalogue.
- DiscoverDx Biomarker Discovery Engine Hurdle's proprietary multi-omics AI-powered biomarker discovery engine used to co-develop novel diagnostics with partners such as Bayer, accelerating biomarker R&D across genomic, epigenomic, proteomic, and lipidomic data.
- Hurdle Diagnostics API Platform Robust REST API that powers the full end-to-end diagnostic testing workflow from ordering, billing, and fulfilment triggering to results delivery, integrated into partner systems with extensive developer documentation and support.
- Test Catalogue (400+ validated tests) Comprehensive catalogue of 400+ clinically validated diagnostic tests covering hormones, wellness, metabolic health, fertility, thyroid, liver function, vitamins, and specialty panels, available through the Hurdle partner portal and Clinics OneDX.
- InflammAge Saliva-Based Epigenetic Biomarker Saliva-based epigenetic biomarker that quantifies chronic inflammation during human aging, co-developed by Hurdle and Bayer using the DiscoverDx engine, validated in the Generation Scotland biobank, and deployed as an at-home CE-marked diagnostic via the Hurdle DaaS platform.
- Epigenetic Biological Age Test World's first saliva-based NGS epigenetic biomarker for quantifying biological age, developed by Hurdle scientists and deployed as a CE-marked diagnostic through the Hurdle DaaS platform and partner channels.
Companies that use Hurdle
Customer profileNamed customers9 records
Segments5 records
Ideal customer profiles6 records
Hurdle technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability8 records
Feature10 records
Hurdle partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered flagship / core and core.
- Bayerflagship / coreBayer and Hurdle formed a strategic precision health partnership to develop and launch personalised diagnostics for healthy aging. Using Hurdle's DiscoverDx AI biomarker engine, the companies developed the InflammAge chronic inflammation biomarker, validated it in Generation Scotland (one of the world's largest epigenetic biobanks), and deployed it as an at-home saliva diagnostic via Hurdle's DaaS platform. Karl Wishart, Global R&D Emerging Science & Innovation Director at Bayer Consumer Health, described working with Hurdle for over 2 years on novel diagnostics co-development. The partnership created a scalable digital ecosystem for personalised health management.
- Lindus HealthcoreLindus Health partnered with Hurdle on clinical trials investigating treatments for pre-diabetes and flu. Hurdle provides decentralised diagnostic infrastructure enabling remote patient testing. Michael Young, Co-Founder at Lindus Health, described Hurdle as understanding the needs of health tech pioneers and being an incredible team to work with.
Scale indicators6 records
Recent moves7 records
Expansion highlights6 records
Hurdle competitors and assessment
Company assessmentDirect peers
- Tempus AI: US-based multi-omics AI platform combining genomic, transcriptomic and clinical data for biomarker discovery and diagnostics, selling to pharma, providers and CROs. Most directly comparable to Hurdle's DiscoverDx + DaaS positioning but at materially larger scale.
- Function Health: Consumer health platform offering a broad battery of diagnostic tests with personalised, longitudinal results. Comparable to Hurdle's white-label digital-medicine and consumer-health-brand offering, including the recurring-test, at-home model.
- Elysium Index: Direct-to-consumer epigenetic biological age test backed by academic research and partnerships. Closest conceptual competitor to Hurdle's saliva-based NGS biological-age biomarker and InflammAge chronic-inflammation biomarker.
- Medable: Decentralised and hybrid clinical trial platform providing remote patient assessments, eCOA and connected diagnostics. Highly comparable to Hurdle's CRO segment, where it underpins decentralised trial diagnostics infrastructure.
- Thriva: UK-based at-home blood-testing and personalised health insights platform. Comparable in the UK consumer / private-provider diagnostic value chain, where Hurdle also offers at-home sample collection and partner-branded kits.
- Daye: UK-based diagnostic startup offering at-home vaginal and other sample collection kits with lab processing and digital follow-up. Comparable in the white-label / branded at-home kit + accredited lab + digital dashboard model.
Broad incumbents
- Guardant Health: Established liquid-biopsy and multi-omics diagnostics company serving oncologists, biopharma and researchers. Comparable in multi-omics + clinical-decision-support use cases, and a likely competitor for Hurdle's pharma and CRO biomarker deals.
- Foundation Medicine: Roche-owned molecular diagnostics and multi-omics profiling company used by oncologists and biopharma for biomarker-driven treatment selection. Highly comparable in the biomarker discovery and pharma CDx space where Hurdle is building.
- Labcorp: Global clinical laboratory and diagnostics-services giant offering routine and specialty testing plus clinical trial and pharma development services. Comparable as both a potential lab-network partner and a competitor for enterprise diagnostic contracts.
Regional players
- Genomics England: UK government-backed organisation running large-scale genomic and multi-omic programmes linked to the NHS. Comparable to Hurdle's federated multi-omics work with biobanks such as Generation Scotland and the UK Biobank ecosystem.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Hurdle social profiles
Digital presenceHurdle compliance and trust
Trust signalCompliance14 records
Hurdle financial estimates
Financial estimateRevenue estimate
Valuation estimate
Hurdle leadership team
Management profileNumber of profiles
Profiles7 records
Hurdle funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Hurdle M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Hurdle
What does Hurdle do?
Hurdle combines AI-driven multi-omics biomarker R&D with an end-to-end Diagnostics-as-a-Service (DaaS) platform for enterprise healthcare customers. Its integrated offering spans proprietary biomarker discovery (DiscoverDx AI engine), CE/UKCA-marked custom-branded sample collection kit manufacturing, a UKAS/CQC-accredited lab testing network, logistics and fulfilment, a white-labelled digital patient experience, and a partner dashboard accessible via a unified API or no-code interface.
Is Hurdle a public or private company?
Hurdle is a private company. It is classified as venture growth investor backed and is currently operating.
When was Hurdle founded?
Hurdle was founded in 2017. It employs 51 to 100 people.
Where is Hurdle based?
Hurdle is headquartered in London, United Kingdom, in the Europe region.
How does Hurdle make money?
Five revenue lines are on record. Biomarker R&D Services are the primary driver. The others are diagnostics-as-a-Service (DaaS), sample Collection Kit Sales, digital Medicine Platform Licensing and lab Testing Services.
Who are Hurdle's main competitors?
Direct peers on record are Tempus AI, Function Health, Elysium Index, Medable, Thriva and Daye. Broad incumbents are Guardant Health, Foundation Medicine and Labcorp. Genomics England is listed as a regional player.
Does Hurdle have an API?
Yes. Hurdle provides a robust API that can power an entire end-to-end diagnostic testing workflow, from ordering, billing, and triggering fulfilment to delivering results. The API enables seamless integration into existing systems with extensive developer support and documentation. Developer documentation is at docs.hurdle.bio.
What industry is Hurdle in?
Hurdle's product category is Diagnostics-as-a-Service Platform. Its primary akta.pro industry code is HLAAANAF, Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics), with a secondary code of HLAGAJAD, Bioinformatics & Multi-omics Analysis Software. Its NAICS code is 5417 and its SIC code is 8071.